Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled Trial of Huazhi Rougan Granule Combined With High-Dose Dual Therapy for Helicobacter Pylori Infection Complicated With Metabolic-associated Steatohepatitis (Dampness-Heat Accumulation Syndrome)

NCT07159412 is registered in ClinicalTrials.gov with Nanjing First Hospital, Nanjing Medical University as lead sponsor.

NCT NCT07159412
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07159412 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled Trial of Huazhi Rougan Granule Combined With High-Dose Dual Therapy for Helicobacter Pylori Infection Complicated With Metabolic-associated Steatohepatitis (Dampness-Heat Accumulation Syndrome)
Lead sponsor
Nanjing First Hospital, Nanjing Medical University
Phase
Not applicable
Overall status
Not yet recruiting
Start date
August 31, 2025
Completion date
August 31, 2027
Enrollment
286 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

helicobacter pylori infection, high-dose dual therapy, huazhi rougan granule, metabolic-associated steatohepatitis